We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi SAN 1.00% agreed to buy Blueprint Medicines BPMC -0.15% for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in ...

Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) soared 26.5% after Sanofi (NASDAQ:SNY) revealed plans to acquire the biopharmaceutical company in a deal valued at approximately $9.5 billion. The ...

As per Sanofi’s statement, the deal involves a cash payment of USD129 per share, representing a roughly 27 percent premium over Blueprint’s most recent closing stock price of USD101.35.

The French pharmaceutical giant struck a deal to buy the Cambridge biotech for about $9.1 billion, or $129 per share. Blueprint’s (Nasdaq: BPMC) shares began trading at $103.17 apiece on Monday ...

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck ...

Blueprint’s CEO, Kate Haviland, expressed pride in the company’s innovations and collaborations that have improved patient outcomes. She anticipates that the merger with Sanofi will accelerate their ...

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company ...

Sanofi SAN -1.02%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Sanofi’s offer to purchase Blueprint includes a payment of $129.00 per share in cash, which is a 27% premium over Blueprint’s closing price on May 30, 2025.

The deal with Blueprint, a Cambridge, Mass.-based immunology-disease specialist, is set to give Sanofi ownership over both an approved drug and an early-stage immunology pipeline, the companies said.